Sanofi Looks To Future After Difficult 2019
Executive Summary
With Consumer Healthcare sales down for Sanofi in 2019, CEO Hudson says the firm must do more to turn performance around. Key to achieving this will be the creation of a more agile standalone OTC business.
You may also be interested in...
Sanofi Continues Consumer Health Trim, Sells Kaopectate US Rights To Arcadia
Sanofi sells US rights to anti-diarrhea Kaopectate brand to Arcadia Consumer Healthcare, which plans to invest in marketing and innovation behind the brand. Arcadia also markets the Nizoral dandruff shampoo and Fungi-Nail consumer health brands.
Tighter Controls For Pseudoephedrine OTCs In France
Popular OTC drugs from J&J, Sanofi and Reckitt Benckiser are among those affected by new rules for the dispensing of pseudoephedrine-containing products in France following a spike in adverse events related to misuse of oral vasoconstrictors.
French OTC Industry Frustrated By Regulatory Clampdown in 2019
Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.